Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cGETS: cGMP Enhancing Therapeutic Strategy for HFpEF
2012-002877-71Phase 2Active
- Sponsor
- European Commission FP7 Health 2010
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tadalafil in heart failure with preserved ejection fraction (HFpEF), systemic arterial hypertension (HTN), pulmonary hypertension (PH), Overweight, obesity, sponsored by European Commission FP7 Health 2010. Started Nov 2013; status: active.
02
Drugs
tadalafil
03
Conditions
heart failure with preserved ejection fraction (HFpEF)systemic arterial hypertension (HTN)pulmonary hypertension (PH)Overweightobesity
Beyond the preview
Go deeper on 2012-002877-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002877-71.